Notably, patients with anti-PD-1/PD-L1-resistant advanced RCC achieved clinical benefit in a phase I trial of CSF1R inhibitor (cabiralizumab) and CD40 agonist (sotigalimab) (Weiss et al., 2021). The gene discussed is CD40; the disease is renal cell carcinoma.